Journal
JOURNAL OF INFECTION AND PUBLIC HEALTH
Volume 15, Issue 1, Pages 123-131Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.jiph.2021.10.021
Keywords
COVID-19; Vaccine; Innovation; Development; Patent; SARS-CoV-2 viral spike (S) protein; Viral receptor-binding domain
Ask authors/readers for more resources
As of July 2021, there have been more than 125 million confirmed cases of COVID-19 worldwide. Vaccines are considered the most effective measure in preventing and controlling the virus. Currently, there are over 292 COVID-19 vaccine candidates in development, with 184 of them in human preclinical trials. Major vaccine developers have filed patent applications to protect their innovative vaccines, and there have also been numerous patent applications related to COVID-19 vaccines developed using different technologies.
More than 125 million confirmed cases of COVID-19 have been reported globally with rising cases in all countries since the first case was reported. A vaccine is the best measure for the effective prevention and control of COVID-19. There are more than 292 COVID-19 candidates' vaccines being developed as of July 2021 of which 184 are in human preclinical trials. A patent provides protection and a marketing monopoly to the inventor of an invention for a specified period. Therefore, vaccine developers, including Moderna, BioNTech, Janssen, Inovio, and Gamaleya also filed patent applications for the protection of their vaccines. This review aims to provide an insight into the patent literature of COVID-19 vaccines. The patent search was done using Patentscope and Espacenet databases. The results have revealed that most of the key players have patented their inventive COVID-19 vaccine. Many patent applications related to COVID-19 vaccines developed via different technologies (DNA, RNA, virus, bacteria, and protein subunit) have also been filed. The publication of a normal patent application takes place after 18 months of its filing. Therefore, many patents/patent applications related to the COVID-19 vaccine developed through different technology may come into the public domain in the coming days. (c) 2021 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons. org/licenses/by-nc-nd/4.0/).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available